THE CONSUMER WHO ARRIVED EARLY
How Three Apparently Parallel Narratives Converge at the Level of Biological Mechanism and what that Convergence Means for the Future of Cosmetics and Wellness
You can take all the NAD+ in the world and still be ageing faster than your neighbours. The conversation around longevity and the conversation around endocrine disruptors travel on separate tracks, as if they shared nothing. And yet they share biological mechanisms. Precisely the same ones.
Inflammaging. Cellular senescence. Mitochondrial dysfunction. Epigenetic drift. Disruption of the hypothalamic–pituitary–adrenal axis. These are the hallmarks of ageing described by López-Otín and colleagues in Cell in 2023, and they are also the documented effects of bisphenol A, phthalates, parabens, and PFAS, as consolidated by the Endocrine Society’s second Scientific Statement on endocrine-disrupting chemicals.
None of this is speculative. Phthalates are associated with mitochondrial dysfunction and impaired fatty acid oxidation. Parabens bind to oestrogen receptors and alter adipose tissue signalling. Bisphenol A accelerates cellular senescence and promotes chronic low-grade inflammation in endothelial tissue. PFAS persist in the bloodstream for years, disrupting thyroid function and lipid metabolism. The literature exceeds two decades old.
The paradox is uncomfortable. A growing share of the public takes spermidine, metformin or NAD+ in the morning and at night and applies it to the skin, which, by the way, is a neuro- immuno-endocrine organ, not an inert surface. Therefore, products that introduce molecules are capable of activating the very pathways the supplement is trying to slow down. This contradiction sits at the centre of what the new science of beauty is genuinely about: the shift from anti-ageing to proactive cellular health cannot be credible if it is built on top of an unexamined cosmetic exposure.
And here is where the argument becomes genuinely systemic. Once those molecules cross the stratum corneum, they do not stay in the dermis. Some enter systemic circulation. They accumulate in adipose tissue and reach the liver, the thyroid, the gonads and the adrenal glands, and in the case of the most lipophilic compounds, they cross the blood–brain barrier. Biomonitoring surveys conducted on industrialised populations detect phthalates, parabens, bisphenols, and PFAS in the blood and urine of nearly every adult tested. The same biomarkers that longevity medicine uses to measure biological ageing – high-sensitivity C- reactive protein, fasting insulin, insulin-like growth factor 1, epigenetic clocks, and heart rate variability – respond directly to that chronic burden. The exposure is not dermatological. It is systemic by definition.
This evidence is the missing link between the two narratives. The longevity industry measures ageing through systemic markers. The endocrine disruptor literature describes substances that move through the same systems, bind to the same receptors and shift the same marker in the wrong direction. Once we establish that connection, the two conversations cease to be parallel and merge into one.
There is a further dimension that is almost always treated as separate and should not be. Mental wellness is not a parallel concern to ageing; it is one of its central biological drivers. Chronic psychological stress disrupts the hypothalamic–pituitary–adrenal axis, shortens telomeres, speeds up epigenetic ageing, and keeps inflammation going.
Poor sleep impairs glymphatic clearance, compromises hormone regulation and reduces DNA repair capacity. Reduced vagal tone, measurable through heart rate variability, tracks almost every degenerative trajectory of modern medicine. The Harvard Study of Adult Development, which has followed its cohort for more than eighty years, found the quality of relationships to predict late-life health outcomes more strongly than cholesterol levels. And the same endocrine disruptors that reach the liver and thyroid also cross the blood–brain barrier, alter neurotransmission, and contribute to the rising prevalence of anxiety, depression, and cognitive decline. Mental wellness is not an emotional concern placed alongside a biological one. It is the same biology, expressed through a different organ.
There is a reason these conversations have remained separate for so long. The longevity industry sells interventions that consumers add to their lives. The endocrine disruptor conversation asks the consumer to remove exposures they already have. The mental wellness conversation asks for something harder still: a different relationship with time, rest and other people. Only the first narrative is easy to sell.
Talking about longevity without mentioning endocrine disruptors and mental wellness is like treating diabetes while ignoring diet and sleep. Eventually, someone will have to bring the three conversations together.
The kind of professional who can hold all three dimensions in mind at once—formulator, toxicologist, endocrinologist, clinician, and storyteller—is the hybrid thinker the next decade of cosmetics and wellness will demand. If those are the questions defining your brand’s next chapter, we would welcome the conversation. And the sooner, the better.